Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 52Ovarian Neoplasms 36Carcinoma, Hepatocellular 36Neoplasms 23Fallopian Tube Neoplasms 21Carcinoma, Non-Small-Cell Lung 19Endometrial Neoplasms 12Breast Neoplasms 11Colonic Neoplasms 10Neoplasm Metastasis 8Lung Neoplasms 8Liver Neoplasms 8Glioblastoma 8Brain Neoplasms 8Uterine Cervical Neoplasms 7Rectal Neoplasms 7Stomach Neoplasms 6Glioma 5Carcinoma, Ovarian Epithelial 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Biliary Tract Neoplasms 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Peritoneal Neoplasms 3Pancreatic Neoplasms 3Neoplasms, Nerve Tissue 3Gastrointestinal Neoplasms 3

Interventions

pembrolizumab 1Pemetrexed 1Control Groups 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Processes × Bevacizumab × 90 days × Clear all
NCT05797246 2026-05-22

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡